Fidelio acquires Indical Bioscience, a leading provider of diagnostic products specifically developed for veterinary specific applications.
The company develops and markets diagnostic solutions and products based on PCR (molecular) and ELISA (immunodiagnostic) technology. The products are used by laboratories primarily to indicate and diagnose viruses and bacteria in production animals, to counteract proliferation and contribute to better animal and human health.
Indical Bioscience is based in Germany and serves customers in 169 countries through its own sales force and commercial partners. Fidelio Capital acquired Indical Bioscience through a carve-out from Qiagen, a molecular diagnostic group listed on the NYSE and Frankfurt stock exchanges.
Odevo, an international leader that is driving change in the traditional property management industry, continues its rapid expansion in the US market with the addition of the leading property manager in the Carolinas, William Douglas Management. William Douglas manages overRead more
Fidelio Capital (“Fidelio”) marks a significant milestone with the successful closing of its latest investment mandate (“Fidelio III”), with total capital commitments in excess of the EUR 1 billion target, which is more than triple the size of its previousRead more
REQS System AB now becomes part of the iBinder Group and strengthens the group’s offering in property management, inspections, and controlling. The acquisition is an important step in iBinder’s goal of creating a simple platform for the property’s entire lifeRead more